GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

cirtociclib   Click here for help

GtoPdb Ligand ID: 13297

Synonyms: BLU-222 | BLU222
Compound class: Synthetic organic
Comment: BLU-222 is an oral cyclin-dependent kinase 2 (CDK2)-selective inhibitor from Blueprint Therapeutics. Its chemical structure was revealed during the first time disclosures session at the 2024 ACS spring meeting in New Orleans. BLU-222 is proposed to target solid tumours with CDK2/cyclin E1 amplifications that drive G1/S progression, such as certain ovarian cancers. The chemical structure of BLU-222 is identical to that for the INN cirtociclib (proposed list 132, Feb. 2025).

cirtociclib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 95.2
Molecular weight 365.34
XLogP 1.73
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1COCCC1CN2C3=NC(=CN=C3C=N2)NC4=CC(=NN4)OC(F)F
Isomeric SMILES C1COCCC1CN2C3=NC(=CN=C3C=N2)NC4=CC(=NN4)OC(F)F
InChI InChI=1S/C15H17F2N7O2/c16-15(17)26-13-5-11(22-23-13)20-12-7-18-10-6-19-24(14(10)21-12)8-9-1-3-25-4-2-9/h5-7,9,15H,1-4,8H2,(H2,20,21,22,23)
InChI Key IFJSYTKOMJJYNP-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
BLU-222 was an anti-tumour clinical candidate. Blueprint Medicines announced discontinuation of development in early 2025, and that they would be prioritising development of their other CDK programs (including CDK2 inhibitor BLU-956, and CDK2 and CDK2 degraders) in breast cancer and other solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05252416 (VELA) Study of BLU-222 in Advanced Solid Tumors Phase 1/Phase 2 Interventional Blueprint Medicines Corporation